Argos Wealth Advisors LLC Purchases Shares of 9,621 Johnson & Johnson $JNJ

Key Points

• Argos Wealth Advisors initiated a new position in Johnson & Johnson, buying 9,621 shares valued at about $1.99 million. The stake represents roughly 0.6% of the firm’s portfolio.
• Johnson & Johnson reported better-than-expected quarterly results, with EPS of $2.70 versus $2.68 expected and revenue of $24.06 billion, up 9.9% year over year. The company also raised its FY2026 EPS guidance to 11.45-11.65.
• The company increased its quarterly dividend to $1.34 per share from $1.30, implying an annualized payout of $5.36 and a yield of about 2.4%. Analyst sentiment remains positive overall, with a consensus rating of Moderate Buy.

Argos Wealth Advisors LLC purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 9,621 shares of the company's stock, valued at approximately $1,991,000. Johnson & Johnson accounts for approximately 0.6% of Argos Wealth Advisors LLC's investment portfolio, making the stock its 24th largest position.

Several other hedge funds have also bought and sold shares of JNJ. Vanguard Group Inc. boosted its stake in shares of Johnson & Johnson by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company's stock worth $49,740,362,000 after acquiring an additional 3,731,074 shares during the period. Capital International Investors boosted its stake in shares of Johnson & Johnson by 545.6% in the third quarter. Capital International Investors now owns 3,865,050 shares of the company's stock worth $716,657,000 after acquiring an additional 3,266,354 shares during the period. Amundi boosted its stake in shares of Johnson & Johnson by 19.3% in the third quarter. Amundi now owns 13,354,936 shares of the company's stock worth $2,512,719,000 after acquiring an additional 2,163,838 shares during the period. Marshall Wace LLP boosted its stake in shares of Johnson & Johnson by 126.3% in the third quarter. Marshall Wace LLP now owns 3,584,162 shares of the company's stock worth $664,575,000 after acquiring an additional 2,000,609 shares during the period. Finally, Danske Bank A S bought a new position in shares of Johnson & Johnson in the third quarter worth about $367,467,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Up 1.4%

Shares of JNJ stock opened at $224.44 on Wednesday. Johnson & Johnson has a 1 year low of $146.12 and a 1 year high of $251.71. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The stock's 50 day simple moving average is $236.18 and its two-hundred day simple moving average is $221.21. The company has a market cap of $540.28 billion, a PE ratio of 25.95, a price-to-earnings-growth ratio of 2.17 and a beta of 0.27.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. During the same period in the prior year, the business posted $2.77 earnings per share. The company's revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Research analysts predict that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be paid a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.4%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Tuesday, May 26th. Johnson & Johnson's payout ratio is currently 60.12%.

Analyst Ratings Changes

JNJ has been the subject of a number of recent analyst reports. Bank of America upped their price objective on Johnson & Johnson from $253.00 to $254.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 15th. Stifel Nicolaus upped their price objective on Johnson & Johnson from $220.00 to $250.00 and gave the stock a "hold" rating in a research note on Wednesday, April 15th. Daiwa Securities Group upped their price objective on Johnson & Johnson from $237.00 to $246.00 and gave the stock an "outperform" rating in a research note on Thursday, April 16th. The Goldman Sachs Group upped their price objective on Johnson & Johnson from $265.00 to $275.00 and gave the stock a "buy" rating in a research note on Wednesday, April 15th. Finally, Guggenheim boosted their target price on Johnson & Johnson from $244.00 to $266.00 and gave the stock a "buy" rating in a research report on Monday, April 20th. Eighteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $252.48.

Insider Activity at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares of the company's stock, valued at $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the transaction, the executive vice president directly owned 26,769 shares in the company, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 30,142 shares of company stock worth $7,360,528. 0.16% of the stock is owned by insiders.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J says Tremfya and newly approved Icotyde will anchor its post-Stelara immunology strategy, helping support growth as Stelara faces biosimilar competition.
• Positive Sentiment: The company launched the Shockwave C2 Aero Coronary IVL catheter globally, reinforcing momentum in its medtech division and expanding its cardiovascular portfolio.
• Positive Sentiment: J&J continues to highlight strong Phase 3 TREMFYA data and new neuropsychiatry portfolio results, which could improve confidence in its pipeline and future launches.
• Neutral Sentiment: J&J will participate in the Goldman Sachs Global Healthcare Conference, which may offer investors more color on strategy but is not, by itself, a major fundamental catalyst.
• Neutral Sentiment: Broader market weakness, especially pressure on the Nasdaq from chip stocks, may be influencing overall sentiment, but it is not specific to J&J’s business.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.